| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Cefminox sodium primarily targets penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. By binding to these proteins, it inhibits the final transpeptidation step of peptidoglycan synthesis, leading to bacterial cell lysis and death. It is also a dual agonist of the prostacyclin receptor (IP) and PPARγ, which upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling.
|
|---|---|
| ln Vitro |
In vitro, cefminox sodium exhibits potent antibacterial activity against a wide range of Gram-negative and anaerobic bacteria. Its activity is due to its stability against beta-lactamases, which are enzymes produced by bacteria to resist antibiotics. The antibiotic's effectiveness is determined by measuring its minimum inhibitory concentration (MIC) against various bacterial strains.
|
| ln Vivo |
In vivo, cefminox sodium is used as an antibiotic to treat various bacterial infections. Studies have shown its effectiveness in treating infections in the fields of obstetrics and gynecology, pediatrics, and for prophylaxis of postoperative infections. It has also been studied for its pharmacokinetics and antimicrobial effect in experimental models of purulent peritonitis.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for cefminox sodium involves measuring its affinity for penicillin-binding proteins (PBPs). This is typically done using a competition binding assay with a radiolabeled penicillin, such as [¹⁴C]-benzylpenicillin, and isolated bacterial membranes. The concentration of cefminox required to displace 50% of the bound radiolabeled penicillin (IC50) is determined.
|
| Cell Assay |
In vitro cellular assays for cefminox sodium are the standard antimicrobial susceptibility tests. The minimum inhibitory concentration (MIC) is determined using broth dilution or agar dilution methods against a panel of bacterial strains. The bacteria are cultured in the presence of increasing concentrations of cefminox, and the lowest concentration that inhibits visible growth is recorded as the MIC.
|
| Animal Protocol |
In vivo animal experiments for cefminox sodium involve mouse models of infection. For example, in a model of purulent peritonitis, mice are injected intraperitoneally with a pathogenic bacteria (e.g., E. coli). Cefminox is then administered (e.g., intravenously or subcutaneously), and the survival rate or bacterial count in the peritoneal fluid is measured to assess its therapeutic efficacy.
|
| ADME/Pharmacokinetics |
In humans, after a 1-gram intravenous injection, cefminox concentrations in serum remain therapeutic for several hours. In beagle dogs, the biological half-life of cefminox in serum was found to be 37.0 minutes. The drug is distributed to various tissues, including the uterus, its appendages, and lung tissue. The pharmacokinetic parameter (K1i/K2i) derived from serum and tissue concentrations correlates well with maximum tissue concentrations.
|
| Toxicity/Toxicokinetics |
Cefminox sodium is generally well-tolerated. As with other beta-lactam antibiotics, the most common adverse reactions are allergic reactions (rash, urticaria) and gastrointestinal disturbances (diarrhea, nausea). Serious adverse reactions like anaphylaxis are rare. It should be used with caution in patients with a history of penicillin allergy due to the risk of cross-reactivity.
|
| References | |
| Additional Infomation |
Cefminox sodium is the sodium salt form of cefminox, a semi-synthetic second-generation β-lactamase-stabilized cephalosporin with antibacterial activity. See also: Cefminox sodium (preferred).
Cefminox sodium is marketed under the brand name Meicelin. It is primarily used clinically as an antibiotic. Its additional activity as a dual agonist of the prostacyclin receptor (IP) and PPARγ suggests it may have other pharmacological effects beyond its antibacterial action. It is a second-generation cephamycin, which means it has a methoxy group at the 7-alpha position, conferring stability against beta-lactamases. |
| Molecular Formula |
C16H20N7NAO7S3
|
|---|---|
| Molecular Weight |
541.5478
|
| Exact Mass |
541.048
|
| CAS # |
75498-96-3
|
| Related CAS # |
(6R,7S)-Cefminox sodium heptahydrate;92636-39-0
|
| PubChem CID |
60196336
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
869
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
[Na+].OC(C(CSCC(N[C@@]1(C(=O)N2C(=C(CS[C@H]12)CSC1=NN=NN1C)C([O-])=O)OC)=O)N)=O
|
| InChi Key |
SBIDXLKJYJVQOE-ZMUPEPPLSA-M
|
| InChi Code |
InChI=1S/C16H21N7O7S3.Na/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/q+1/p-1/t8?,14-,16+/m1./s1
|
| Chemical Name |
sodium (6R,7S)-7-(2-((2-amino-2-carboxyethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
MT141MT-141 Cefminox SodiumMT 141 Meicelin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~83.33 mg/mL (~153.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (92.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8466 mL | 9.2328 mL | 18.4655 mL | |
| 5 mM | 0.3693 mL | 1.8466 mL | 3.6931 mL | |
| 10 mM | 0.1847 mL | 0.9233 mL | 1.8466 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
